Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire
- PMID: 20651199
- PMCID: PMC6247784
- DOI: 10.2214/AJR.09.3803
Screening patients to assess renal function before administering gadolinium chelates: assessment of the Choyke questionnaire
Abstract
Objective: The purpose of our study was to determine the efficacy of using the Choyke questionnaire to stratify the potential risk for nephrogenic systemic fibrosis (NSF) before a gadolinium-enhanced MRI examination and to compare the economic impact of such an approach with universal blood sampling before gadolinium-enhanced MRI.
Materials and methods: We retrospectively reviewed the records of 1,086 consecutive outpatients referred for gadolinium-enhanced MRI. For inclusion, patients were required to have an estimated glomerular filtration rate (eGFR) result within 30 days before gadolinium-enhanced MRI and a completed Choyke questionnaire, first when the order was placed and again at the point of service. Questionnaire results were dichotomized into "No" (all no responses in both questionnaires) or "Yes" (one or more yes responses in either questionnaire) response groups for comparison with the corresponding eGFR. An economic impact assessment for using the questionnaire to identify "at risk" patients was performed using a decision-analytic model.
Results: Entry criteria were met in 665 of 1,086 (61.2%) patients. Zero patients in the No (n = 287) and seven in the Yes (1.9%) group (n = 378) had an eGFR of less than 30 mL/min/1.73 m(2). Using the 100% sensitivity achieved in identifying higher risk patients (seven patients; 95% CI, 59-100%), the questionnaire could save $4.52 per patient. At the lower boundary of the 95% CI for sensitivity, the savings incurred would come at the expense of administering gadolinium to 0.4% of patients with an eGFR less than 30 mL/min/1.73 m(2).
Conclusion: The Choyke questionnaire effectively stratifies patients for NSF risk before gadolinium-enhanced MRI, offering potential cost savings and streamlined care.
Figures

Similar articles
-
Comparison of the sensitivity of a pre-MRI questionnaire and point of care eGFR testing for detection of impaired renal function.Acad Radiol. 2012 Oct;19(10):1181-5. doi: 10.1016/j.acra.2012.04.016. Epub 2012 Jul 24. Acad Radiol. 2012. PMID: 22831822 Free PMC article.
-
Incidence of nephrogenic systemic fibrosis at two large medical centers.Radiology. 2008 Sep;248(3):807-16. doi: 10.1148/radiol.2483071863. Radiology. 2008. PMID: 18710976
-
Screening for impaired renal function in outpatients before iodinated contrast injection: Comparing the Choyke questionnaire with a rapid point-of-care-test.Eur J Radiol. 2015 Jul;84(7):1227-31. doi: 10.1016/j.ejrad.2015.04.001. Epub 2015 Apr 13. Eur J Radiol. 2015. PMID: 25933722
-
Nephrogenic systemic fibrosis: center case review.J Magn Reson Imaging. 2007 Nov;26(5):1198-203. doi: 10.1002/jmri.21136. J Magn Reson Imaging. 2007. PMID: 17969162 Review.
-
Gadolinium-Based Contrast Agents in Kidney Disease: Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can Assoc Radiol J. 2018 May;69(2):136-150. doi: 10.1016/j.carj.2017.11.002. Can Assoc Radiol J. 2018. PMID: 29706252 Review.
Cited by
-
Concentration-dependent Early Antivascular and Antitumor Effects of Itraconazole in Non-Small Cell Lung Cancer.Clin Cancer Res. 2020 Nov 15;26(22):6017-6027. doi: 10.1158/1078-0432.CCR-20-1916. Epub 2020 Aug 26. Clin Cancer Res. 2020. PMID: 32847935 Free PMC article. Clinical Trial.
-
Can a structured questionnaire identify patients with reduced renal function?Eur Radiol. 2014 Mar;24(3):780-4. doi: 10.1007/s00330-013-3065-x. Epub 2013 Nov 26. Eur Radiol. 2014. PMID: 24275804
-
Gadolinium-Based Contrast Agents in Kidney Disease: A Comprehensive Review and Clinical Practice Guideline Issued by the Canadian Association of Radiologists.Can J Kidney Health Dis. 2018 Jun 12;5:2054358118778573. doi: 10.1177/2054358118778573. eCollection 2018. Can J Kidney Health Dis. 2018. PMID: 29977584 Free PMC article.
-
Nephrogenic systemic fibrosis and gadolinium-based contrast media: updated ESUR Contrast Medium Safety Committee guidelines.Eur Radiol. 2013 Feb;23(2):307-18. doi: 10.1007/s00330-012-2597-9. Epub 2012 Aug 4. Eur Radiol. 2013. PMID: 22865271 Review.
-
Renal imaging in patients with renal impairment.Curr Urol Rep. 2011 Feb;12(1):24-33. doi: 10.1007/s11934-010-0158-9. Curr Urol Rep. 2011. PMID: 21128027 Review.
References
-
- Grobner T Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant, 2006; 21:1104–1108 - PubMed
-
- Marckmann P, Skov L, Rossen K, et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006; 17:2359–2362 - PubMed
-
- Shellock FG, Spinazzi A. MRI safety update 2008. Part I. MRI contrast agents and nephrogenic systemic fibrosis. AJR 2008; 191:1129–1139 - PubMed
-
- Perazella MA, Rodby RA. Gadolinium use in patients with kidney disease: a cause for concern. Semin Dial 2007; 20:179–185 - PubMed
-
- United States Food and Drug Administration. FDA requests boxed warning for contrast agents used to improve MRI images www.fda.gov./NewsEvents/Newsroom/PressAnnouncements/2007/ucm108919.htm. Accessed December 15, 2009
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous